Final data from Sanofi Pasteur's H1N1 vaccine trials supports recommended dosing
This article was originally published in Scrip
Executive Summary
Final results from Phase III trials of Sanofi Pasteur's H1N1 show that two doses are needed for children, whereas one is needed for adults. The data also show that the monovalent vaccine has "a safety profile similar to that typically observed with seasonal influenza vaccine in all age groups studied", says Wayne Pisano, president and CEO of Sanofi Pasteur.